Aclaris Therapeutics
A company developing treatments for dermatology and immunology.
All edits by Lena Kourkouta
Edits on 11 Jan, 2019
Lena Kourkouta
Edits made to:
Article (+15/-15 characters)
Article
ATI-502 is a topical JAK1/JAK3 inhibitor that is being investigated (Phase 2) for alopecia areataalopecia areata, including patchy alopecia areata and the more severe forms of the disease, alopecia totalis and alopecia universalis. The product is also under investigation (Phase 2) for androgenetic alopecia, vitiligo, and atopic dermatitis. In July 2017, Aclaris filed an IND (investigational new drug) application for ATI-502.
Find more companies like Aclaris Therapeutics
Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
